Updated:
GNTech
Dr. Guido Boabaid May's GNTech ships at-home pharmacogentic test kits targeting mental health treatment — reports return in 21 days.
GNTech
Founded in an unspecified year by Dr. Guido Boabaid May, a São Paulo-based psychiatrist and member of the clinical staff at Hospital Israelita Albert Einstein, GNTech operates at the intersection of genetic sequencing and clinical psychiatry. The firm's origin ties directly to Boabaid's frustration with trial-and-error prescribing in mental health — a clinical pattern that the firm's proprietary test panels are designed to disrupt by mapping individual genetic variants against drug metabolism, efficacy, and toxicity risk. GNTech's product line is segmented primarily by clinical indication and breadth of genetic coverage, spanning psychiatric panel tests (PsicoGene Select and PsicoGene Pro) focused on depression, anxiety, ADHD, and autism spectrum disorder, alongside a more expansive TotalGene panel that extends the same pharmacogenomic logic into oncology, cardiology, gastroenterology, and infectious disease. The direct-to-consumer model allows patients to order kits online without a prescription, perform a buccal swab at home, and receive a digital report; the firm also accepts medical requisitions for insurance reimbursement pathways. GNTech cites outcomes on its website including up to a 50% relative improvement in remission rates and a 58% reduction in hospitalizations, with more than 25,000 lives impacted to date. The firm maintains a dual-country footprint with its headquarters in Seongnam, South Korea and a presence in Plymouth, United Kingdom, though the bulk of its commercial traction appears concentrated in Brazil, where Boabaid's clinical reputation and local media coverage drive patient and physician adoption. The company claims over 5,000 partner physicians and a track record of at-scale case resolution, with its research anchored in peer-reviewed findings that 99.5% of individuals carry at least one actionable pharmacogenetic variant. GNTech's structural differentiator is its origin inside a single practicing psychiatrist's caseload — the test panels are designed by the same clinician who interprets them, compressing the typical gap between bioinformatics lab and prescribing physician. This practitioner-led model differentiates it from pure-play lab benchtop genetic test manufacturers, though it introduces reliance on one principal operator for clinical credibility and strategic direction.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
South Korea
City
Seongnam
Corporate office
Seongnam, South Korea
Additional offices
Plymouth, UK
Principals
Dr. Guido Boabaid May
CEO, Founder, Psychiatrist
Sector focus
Frequently asked questions
Who runs investment decisions at GNTech?
GNTech does not publicly disclose a dedicated investment team or a chief investment officer. The firm's website and public-facing materials feature only its founder-clinician, Dr. Guido Boabaid May, suggesting that his dual role as CEO and lead psychiatrist likely centralizes operational and strategic decision-making. There is no named outside investor or board member in the available sources.
How does GNTech source its commercial opportunities?
The firm primarily goes direct to patient via its e-commerce website, where individuals can purchase at-home buccal swab kits without a prescription. It also builds physician-channel volume through its network of more than 5,000 partner doctors who review and interpret the digital reports in clinical settings. Media coverage in Brazilian outlets functions as a third acquisition funnel by amplifying patient success stories.
Which therapeutic areas does GNTech's tests actually cover?
GNTech markets panelized tests across distinct verticals. Its PsicoGene line targets psychiatric conditions — major depressive disorder, generalized anxiety, ADHD, bipolar disorder, and autism spectrum disorder — while the top-tier TotalGene panel adds gene–drug interaction analyses for oncology, cardiology, gastroenterology, and infectious disease agents.
What is GNTech's known posture on clinical evidence and validation?
The firm cites peer-reviewed research on its website, including the finding from McInnes et al. (2020) that 99.5% of individuals carry at least one actionable pharmacogenetic variant, and it references relative outcome improvements from published pharmacogenomic studies. GNTech does not, however, publish its own independent prospective trial data on its website, relying instead on clinical case numbers and third-party literature to support its marketing claims.
Does GNTech operate purely direct-to-consumer or also through institutional healthcare channels?
GNTech operates a hybrid model. Consumers can purchase kits directly online without a prescription, but the company also accepts medical requisitions for cases involving health plans or insurers, positioning the test as reimbursable in certain contexts. The interpretive report must be reviewed by a licensed physician regardless of purchase path, making the product functionally a physician-mediated diagnostic in both B2C and B2B workflows.
What is the relationship between GNTech's South Korean headquarters and its Brazilian commercial activity?
The corporate entity is domiciled in Seongnam, South Korea, with an additional office in Plymouth, UK, yet the firm's sole publicly visible principal, Dr. Guido Boabaid May, practices in São Paulo at Hospital Israelita Albert Einstein. GNTech's commercial website operates under a Brazilian country-code top-level domain (.med.br) and its patient testimonials and press coverage are overwhelmingly Brazilian, suggesting that the South Korean headquarters may serve corporate, R&D, or lab-processing functions while commercial operations concentrate in Brazil.
How is GNTech capitalized, and does it have outside investors?
No information about GNTech's funding structure, outside investors, or institutional backing is publicly available. The firm does not disclose any venture capital rounds, family office backing, or debt facilities on its website or in accessible media. The entity's capital structure remains entirely opaque based on current sources.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: